ມີຄວາມກ້າວໜ້າອັນໃຫຍ່ຫຼວງໃນການພັດທະນາຢາປົວເນື້ອງອກໃນສະໝອງໃນໄວເດັກ. ເນື້ອງອກໃນສະໝອງຂອງເດັກນ້ອຍເປັນພະຍາດທີ່ພົບເລື້ອຍກວ່າໃນເດັກນ້ອຍ. ການຄົ້ນຄວ້າຫຼ້າສຸດໄດ້ພົບເຫັນວ່າຢາຄັອກເທນໃຫມ່ສາມາດປິ່ນປົວເນື້ອງອກໃນສະຫມອງໃນໄວເດັກທົ່ວໄປ.
Cancer Cell” magazine recently announced that in the UK, about 400 children develop brain ເນື້ອງອກ each year, of which the prevalence of boys is slightly higher than that of girls.
Are we able to take advantage of the results of tumor gene testing and tailor-made treatments, a strategy often referred to as personalized medicine? This treatment strategy can produce very good results for patients with brain tumors.
Neural myeloblastoma (medulloblastoma) is one of the most common ເນື້ອງອກຮ້າຍແຮງ of the cerebellum. This ເນື້ອງອກໃນສະ ໝອງ grows rapidly and most often occurs in children around the age of 5. ຕົວເລືອກການຮັກສາ include surgery, radiation, and chemotherapy. Although great progress has been made in treatment methods and techniques, the success rate of treating myeloblastoma still lags far behind other children’s malignancies. In particular, myeloblastoma is a highly aggressive malignancy. Only 40% of patients with medulloblastoma survive, compared with other tumors of a less severe type-with a survival rate of more than 80%.
Researchers in the United States have discovered a new combination therapy for the treatment of highly aggressive neuroblastoma. In laboratory tests, the drug killed ມະເຮັງ cells without any toxicity to normal cells, and researchers hope to conduct clinical trials of the drug. Robert Wechsler-Reya, an adjunct professor at the Sanford Burnham Prebys Medical Institute, said: “Our goal is to confirm that the drug has low toxicity properties. Because doctors and patients in this case urgently require new clinical treatment options, we will soon apply the drug from the laboratory to clinical treatment.
ໂດຍການປະສົມປະສານກັບຢາອື່ນໆ, ສານປະສົມ ໃໝ່ ທີ່ສະກັດກັ້ນເນື້ອງອກຈະຖືກກວດໃນ vitro ແລະໃນ vivo.
ການທົດລອງທາງດ້ານການຊ່ວຍ for neuroblastoma are often very challenging because of the limited number of patients. In addition, coupled with the variability of the disease, most treatments are only effective for one subtype of patient. Understanding which patients will respond to this treatment is one of the main goals of the trial.
"ຖ້າພວກເຮົາສາມາດພັດທະນາການປິ່ນປົວແບບປັບແຕ່ງໂດຍອີງໃສ່ພັນທຸ ກຳ ຂອງເນື້ອງອກ - ຍຸດທະສາດທີ່ມັກຈະເອີ້ນວ່າການປິ່ນປົວແບບເປັນສ່ວນບຸກຄົນ - ສິ່ງນີ້ສາມາດ ນຳ ເອົາຂ່າວປະເສີດອັນໃຫຍ່ຫຼວງມາສູ່ຄົນເຈັບທີ່ມີເນື້ອງອກບາງຢ່າງ."
ໂຣກໂຣກໂຣກໂຣກໂຣກໂຣກໂຣກໂຣກໂຣກໂຣກໂຣກໂຣກໂຣກໂຣກໂຣກໂຣກໂຣກໂຣກໂຣກໂຣກໂຣກໂຣກໂຣກໂຣກໂຣກໂຣກໂຣກໂຣກໂຣກໂຣກໂຣກໂຣກໂຣກໂຣກໂຣກໂຣກໂຣກໂຣກໂຣກໂຣກໂຣກໂຣກໂຣກໂຣກໂຣກໂຣກໂຣກໂຣກໂຣກໂຣກໂຣກໂຣກໂຣກໂຣກໂຣກໂຣກໂຣກໂຣກໂຣກໂຣກໂຣກໂຣກໂຣກໂຣກໂຣກໂຣກໂຣກໂຣກໂຣກໂຣກໂຣກໂຣກນີ້. ໃນທາງກົງກັນຂ້າມ, ການຢູ່ລອດໃນໄລຍະຍາວຂອງໂຣກ neuroblastomas ອື່ນໆແມ່ນຂ້ອນຂ້າງດີ, ແລະປະມານ 40% ຂອງຄົນເຈັບສາມາດຢູ່ລອດໄລຍະຍາວ.
ສ່ວນໃຫຍ່ຂອງກຸ່ມທີສາມຂອງຜູ້ປ່ວຍໂຣກ neuroblastoma ມີການສະແດງອອກສູງຂອງ MYC oncogene, ເຊິ່ງເປັນສາເຫດຂອງການແບ່ງຈຸລັງທີ່ບໍ່ສາມາດຄວບຄຸມໄດ້ແລະການສ້າງເນື້ອງອກ.
There was a study on mice with a third type of neural tube cell tumors that showed histone deacetylase inhibitors (HDACIs) and phosphatidylinositol 3-kinase inhibitors (PI3KIs) might stop mice and people from making neurotubular glioblastomas without doing too much damage to normal cells.
We found several histone deacetylase inhibitors that can kill MYC oncogene-activated neural tube cell tumors without harming normal cell agents (HDACIs),” said Pei Yanxin, an assistant professor at the National Children’s ສູນການແພດ in Washington, DC
The most effective of these compounds is panobinostat, which has entered clinical trials in other ປະເພດຂອງມະເຮັງ, but has not yet been tested on neuroblastoma.” Dr. Kun-Wei, a postdoctoral researcher at Stanford University, added: “Several other studies have revealed that the mechanism of action of panobinostat is to promote the activation of the FOXO1 gene that can interfere with the oncogenes of MYC.
Phosphatidylinositol 3-kinase inhibitors (PI3KIs) are also thought to have the effect of activating the FOXO1 gene. We hypothesized that panobinostat and phosphatidylinositol 3-kinase inhibitors (PI3KIs) could work together to block ເຊນມະເລັງ ຄວາມຢູ່ລອດ.
“It is true that the combined treatment of these two drugs can significantly increase the survival of patients with tumors carrying the MYC gene compared to using a single drug alone.”
